Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles
Autore:
Kol, S; Lightman, A; Hillensjo, T; Devroey, P; Fauser, B; Tarlatzis, B; Mannaerts, B; Itskovitz-Eldor, J;
Indirizzi:
Rambam Med Ctr, Dept Obstet & Gynecol, IL-31096 Haifa, Israel Rambam Med Ctr Haifa Israel IL-31096 t & Gynecol, IL-31096 Haifa, Israel Carlanderska Sjukhuset, Fertilitets Ctr, Gothenburg, Sweden Carlanderska Sjukhuset Gothenburg Sweden litets Ctr, Gothenburg, Sweden Free Univ Brussels, Acad Hosp, B-1090 Brussels, Belgium Free Univ Brussels Brussels Belgium B-1090 osp, B-1090 Brussels, Belgium Acad Hosp Dijkzigt, NL-3000 DR Rotterdam, Netherlands Acad Hosp Dijkzigt Rotterdam Netherlands NL-3000 DR tterdam, Netherlands Infert IVF Ctr Geniki Cliniki, Salonika, Greece Infert IVF Ctr Geniki Cliniki Salonika Greece Cliniki, Salonika, Greece NV Organon, Clin Dev Dept, NL-5340 BH Oss, Netherlands NV Organon Oss Netherlands NL-5340 BH Dept, NL-5340 BH Oss, Netherlands
Titolo Testata:
HUMAN REPRODUCTION
fascicolo: 9, volume: 14, anno: 1999,
pagine: 2242 - 2244
SICI:
0268-1161(199909)14:9<2242:HDOGHA>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
FOLLICLE-STIMULATING-HORMONE; CETRORELIX; RECOMBINANT; EXPRESSION; GANIRELIX; PHASE; GENE;
Keywords:
ganirelix; GnRH antagonist; ovarian stimulation; pregnancy; recombinant human FSH;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
11
Recensione:
Indirizzi per estratti:
Indirizzo: Itskovitz-Eldor, J Rambam Med Ctr, Dept Obstet & Gynecol, IL-31096 Haifa, Israel Rambam Med Ctr Haifa Israel IL-31096 96 Haifa, Israel
Citazione:
S. Kol et al., "High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles", HUM REPR, 14(9), 1999, pp. 2242-2244

Abstract

The clinical application of gonadotrophin-releasing hormone (GnRH) antagonists instead of GnRH agonists, to prevent spontaneous premature luteinizinghormone surge during ovarian stimulation for assisted reproduction treatment has been advocated. A recent, double-blind, dose-finding study, including six dosages of the GnRH antagonist ganirelix, in women undergoing ovarianstimulation with recombinant follicle stimulating hormone (FSH), has indicated that high doses of GnRH antagonist (I or 2 mg once daily) are associated with a low implantation rate. This follow-up study reports on the pregnancy rate after replacement of cryopreserved embryos obtained in stimulationcycles of the above-mentioned trial. Ovarian stimulation was initiated on day 2 of the cycle, with daily injections of 150 IU recombinant FSH, Ganirelix (0.0625, 0.125, 0.25, 0.5, 1.0 or 2.0 mg) was administered once daily from stimulation day 6 onwards, up to and including the day of human chorionic gonadotrophin. Retrieved oocytes were fertilized by in-vitro fertilization (IVF) or intracytoplasmic sperm injection and a maximum of three fresh embryos was transferred. Excess embryos were frozen, and subsequently used in either natural or programmed cycles. Until June 1998, 11 ongoing pregnancies (12-16 weeks after embryo transfer) were achieved from 46 cycles in which embryos had been first frozen (23.9% per transfer). Six of these 11 patients had been treated with a high dose of ganirelix (1.0 or 2.0 mg) during the IVF cycles in which the embryos mere obtained, In conclusion, our data suggest that high dosages of ganirelix do not adversely affect the potential of embryos to establish clinical pregnancy in freeze-thaw cycles.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 17:44:23